Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation
Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation
Active, not recruiting · NCT06780930 · Registry updated 2026-06-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation | Residual or Recurrent Grade 2 IDH Mutant Glioma | Active, not recruiting | Phase 3 | 2026-06-04 | NCT06780930 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Servier | 21 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Chang Gung Memorial Hospital, | Taoyuan | Taiwan | 1 |
| Huashan Hospital Fudan University | Shanghai | China | 17 |
| Sanbo Brain Hospital, Capital Medical University | Beijing | China | 2 |
| Taipei Veterans General Hospital | Taipei | Taiwan | 64 |
| The Second Affiliated Hospital of Air Force Military Medical University | Xi'an | China | 1 |
| The Second People's Hospital of Shenzhen | Shenzhen | China | 1 |
| Tiantan Hospital | Beijing | China | 1 |
| West China Hospital Sichuan University | Chengdu | China | 10 |